Implementation Of Prescription Drug Monitoring Programs Associated With Reductions In Opioid-Related Death Rates

被引:215
|
作者
Patrick, Stephen W. [1 ]
Fry, Carrie E. [2 ]
Jones, Timothy F. [3 ]
Buntin, Melinda B. [4 ]
机构
[1] Vanderbilt Univ, Sch Med, Div Neonatol, Pediat & Hlth Policy, Nashville, TN 37212 USA
[2] Vanderbilt Univ, Sch Med, Dept Hlth Policy, Nashville, TN 37212 USA
[3] Tennessee Dept Hlth, Nashville, TN USA
[4] Vanderbilt Univ, Med Ctr, Dept Hlth Policy, Nashville, TN USA
基金
美国国家卫生研究院;
关键词
UNITED-STATES; OVERDOSE DEATHS; ANALGESICS; MORTALITY; FLORIDA; POLICY; ABUSE; RISK; LAWS;
D O I
10.1377/hlthaff.2015.1496
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Over the past two decades the number of opioid pain relievers sold in the United States rose dramatically. This rise in sales was accompanied by an increase in opioid-related overdose deaths. In response, forty-nine states (all but Missouri) created prescription drug monitoring programs to detect high-risk prescribing and patient behaviors. Our objectives were to determine whether the implementation or particular characteristics of the programs were effective in reducing opioid-related overdose deaths. In adjusted analyses we found that a state's implementation of a program was associated with an average reduction of 1.12 opioid-related overdose deaths per 100,000 population in the year after implementation. Additionally, states whose programs had robust characteristics-including monitoring greater numbers of drugs with abuse potential and updating their data at least weekly-had greater reductions in deaths, compared to states whose programs did not have these characteristics. We estimate that if Missouri adopted a prescription drug monitoring program and other states enhanced their programs with robust features, there would be more than 600 fewer overdose deaths nationwide in 2016, preventing approximately two deaths each day.
引用
下载
收藏
页码:1324 / 1332
页数:9
相关论文
共 50 条
  • [41] Experiences of families bereaved by opioid-related death
    Hicks, Danielle
    Pasman, Emily
    O'Shay, Sydney
    Kcomt, Luisa
    Resko, Stella
    JOURNAL OF SOCIAL WORK PRACTICE IN THE ADDICTIONS, 2024,
  • [42] Prescription drug monitoring programs
    Miller, Michael M.
    Brown, Randall T.
    AMERICAN FAMILY PHYSICIAN, 2007, 75 (06) : 810 - 811
  • [43] CONSIDERING PRESCRIPTION OPIOID-RELATED HARMS IN THE POPULATION: RESPONSE TO COMMENTARIES
    Fischer, Benedikt
    Keates, Annette
    Buehringer, Gerhard
    Reimer, Jens
    Rehm, Juergen
    ADDICTION, 2014, 109 (02) : 186 - +
  • [44] Characterizing opioid-related tweets: a comparison between prescription and illicit opioid chatter
    Sarker, Abeed
    Gonzalez-Hernandez, Graciela
    De Roos, Francis
    Perrone, Jeanmarie
    CLINICAL TOXICOLOGY, 2019, 57 (06) : 475 - 475
  • [45] Must-access prescription drug monitoring programs and retail opioid sales
    Shakya, Shishir
    Hodges, Collin
    CONTEMPORARY ECONOMIC POLICY, 2023, 41 (01) : 146 - 165
  • [46] Prescription Drug Monitoring Programs Needed to Manage Opioid Use in Asia Pacific
    Cheung, Chi-Wai
    PAIN PRACTICE, 2016, 16 (05) : E93 - E93
  • [47] Four States With Robust Prescription Drug Monitoring Programs Reduced Opioid Dosages
    Haffajee, Rebecca L.
    Mello, Michelle M.
    Zhang, Fang
    Zaslavsky, Alan M.
    Larochelle, Marc R.
    Wharam, J. Frank
    HEALTH AFFAIRS, 2018, 37 (06) : 964 - 974
  • [48] IMPACT OF STATE MANDATED QUERIES OF THE PRESCRIPTION DRUG MONITORING PROGRAMS ON OPIOID AND NON-OPIOID DRUG RELATED ADVERSE EFFECTS: A DIFFERENCE IN DIFFERENCE APPROACH
    Hayes, C. J.
    Chopra, D.
    Shah, A. B.
    Martin, B. C.
    VALUE IN HEALTH, 2016, 19 (07) : A622 - A622
  • [49] Prescription Drug Monitoring Programs Combating prescription drug misuse
    Gudoski, Anthony J.
    NURSE PRACTITIONER, 2015, 40 (11): : 28 - 33
  • [50] Medicaid Expansion and Rates of Opioid-Related Hospital Use
    Khokhar, Arshjot
    Mehta, Anuj V.
    John, Kenneth
    JAMA INTERNAL MEDICINE, 2020, 180 (10) : 1401 - 1402